antalarmin has been researched along with lisuride in 1 studies
| Studies (antalarmin) | Trials (antalarmin) | Recent Studies (post-2010) (antalarmin) | Studies (lisuride) | Trials (lisuride) | Recent Studies (post-2010) (lisuride) |
|---|---|---|---|---|---|
| 181 | 0 | 76 | 756 | 80 | 31 |
| Protein | Taxonomy | antalarmin (IC50) | lisuride (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.02 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.041 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.559 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.016 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0029 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0005 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0043 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0005 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.04 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.041 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.003 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.02 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0005 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.16 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0002 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0051 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cador, M; Koob, GF; Stinus, L; Zorrilla, EP | 1 |
1 other study(ies) available for antalarmin and lisuride
| Article | Year |
|---|---|
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Implants; Fluoxetine; Lisuride; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Substance Withdrawal Syndrome; Taurine | 2005 |